Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Valbiotis SA ( (FR:ALVAL) ) has issued an update.
Valbiotis has announced the successful results of its Phase II/III HEART II clinical study on Lipidrive®, proving its efficacy in significantly reducing LDL cholesterol in individuals with mild to moderate hypercholesterolemia. This study, involving over 300 participants, confirms the safety and effectiveness of Lipidrive®, positioning Valbiotis as a leader in developing natural, scientifically-backed health products for cardiovascular disease prevention, potentially impacting the company’s market position positively.
More about Valbiotis SA
Valbiotis is a French scientific research laboratory focusing on the development and marketing of dietary supplements that are scientifically validated to support daily health and prevent metabolic and cardiovascular diseases. The company employs an innovative approach using plant-based resources to create health nutrition products that target metabolic disorders and cardiovascular risk factors, and has received recognition and financial support from the European Union.
YTD Price Performance: 12.97%
Average Trading Volume: 2,394
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €25.22M
See more insights into ALVAL stock on TipRanks’ Stock Analysis page.
